Octagon Therapeutics

📍 United States🗓 Founded 2017👥 10 employees💰 Last funded Apr 2023
Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease.
3
Total investors
1
Early stage
0
Mid stage
2
Late stage
2017
Founded
Investor geography1 country
United States
3
Investor activity2017–2023 · investors recorded per year
2017120232
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Octagon Therapeutics?
Octagon Therapeutics has 3 investors on record on gritt.io, including 1 early-stage backers and 2 late-stage investors.
When did Octagon Therapeutics last raise funding?
The most recent investment in Octagon Therapeutics recorded on gritt.io was in April 2023.
When was Octagon Therapeutics founded?
Octagon Therapeutics was founded in 2017.
What industry is Octagon Therapeutics in?
Octagon Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Octagon Therapeutics based?
Octagon Therapeutics is headquartered in United States.